President Donald Trump has reached drug-pricing agreements with 26 pharmaceutical companies, including BeiGene, to narrow a gap in which U.S. prescription costs are often nearly three times higher than in other developed countries. The agreements include most-favored-nation (MFN) pricing for Medicaid, discounts of up to 85% through TrumpRx.gov, direct-to-patient sales, U.S. investment and active pharmaceutical ingredient donations, with companies receiving or seeking tariff relief. BeiGene’s voluntary agreement, announced by the White House on Aug. 31 U.S. local time, covers only its PD-1 inhibitor tislelizumab, marketed as Tevimbra, at confidential negotiated Medicaid prices reaching about 8% of the drug’s U.S.-approved indication patient base; Zanubrutinib, marketed as Brukinsa and the company’s main U.S. revenue driver, remains outside the agreement. The administration says the 26 participants represent about 90% of the domestic pharmaceutical market, while BeiGene’s disclosure describes coverage of 89% of the U.S. branded-drug market. White House economists estimated $529 billion in savings over the next decade and $64.3 billion in federal and state Medicaid savings, while the nine newer participants committed at least $19.6 billion to near-term U.S. manufacturing.